Careers  |  Sign In  |  Register

Ovarian Cancer Drug Receives Expedited Approval From FDA

The LA Times reports that a new ovarian cancer treatment has just received an accelerated FDA approval. Lynparza successfully shrunk or eliminated ovarian tumors during clinical trials in women presenting ovarian cancer with a specific genetic fingerprint and had received three rounds of chemotherapy treatment. Additionally, approval has been given for a “companion diagnostic” test, BRACAnalysis by Myriad to identify appropriate candidates for the new drug.

Read it in the LA Times.